

## References

I-222

1. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019; 59(1):1-18
2. Deng H, Li G, Nie H, et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. *BMC Neurology*. 2020;20(1):1-12
3. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). *Cephalalgia*. 2020. 40(3):241-254
4. Vyepiti (eptinezumab-jjmr) injection, for intravenous use [package insert]. Lundbeck Seattle BioPharmaceuticals, Inc. Bothell, WA. Revised 10/2022.
5. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Eptinezumab.
6. Micromedex DrugDex Compendium®. 2024. Eptinezumab
7. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
8. Eptinezumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 31, 2022.